[Clinical and immunologic studies of the use of thymus polypeptide factor (thymostimulin) in chronic mucocutaneous candidiasis].
T-cell lymphocyte subpopulations were successfully converted by means of thymus polypeptide factor in a 17-year-old boy with chronic mucocutaneous candidiasis and combined immunodeficiency. It was demonstrated that the injections caused normalization of the peripheral T-lymphocytes subpopulations and a better state of general health. Normalization was due to a minimal increase in total peripheral T-lymphocytes and T-helper cells and a significant decrease in T-suppressor cells.
D000293:Adolescent; D002177:Candidiasis / Q000188:drug therapy*; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D013601:T-Lymphocytes / Q000145:classification / Q000187:drug effects* / Q000276:immunology; D013949:Thymus Extracts / Q000627:therapeutic use*
D007136:Immunoglobulins; D013949:Thymus Extracts; C031407:thymostimulin
Klinische und immunologische Beobachtungen während der Gabe von Thymuspolypeptidfaktor (Thymostimulin) bei chronischer mukokutaner Kandidose.